| Neuromyelitis optica spectrum disorder | Diagnostic method | Symptoms, blood antibody titers, MRI | 1.00 | infobox |
| Neuromyelitis optica spectrum disorder | Differential diagnosis | Multiple sclerosis, various autoimmune disorders | 1.00 | infobox |
| Neuromyelitis optica spectrum disorder | Frequency | Up to 1 in 10,000 | 1.00 | infobox |
| Neuromyelitis optica spectrum disorder | Medication | Eculizumab, ravulizumab, inebilizumab, satralizumab, rituximab, methylprednisolone, azathioprine, cellCept, mitoxantrone, methotrexate, intravenous immunoglobulin, cyclophosphamide | 1.00 | infobox |
| Neuromyelitis optica spectrum disorder | Other names | Neuromyelitis optica (NMO), Devic's disease, Devic's syndrome | 1.00 | infobox |
| Neuromyelitis optica spectrum disorder | Risk factors | Female sex, genetic factors | 1.00 | infobox |
| Neuromyelitis optica spectrum disorder | Specialty | Neurology, ophthalmology | 1.00 | infobox |
| Neuromyelitis optica spectrum disorder | Symptoms | Vision loss, sensory loss, weakness, bladder dysfunction | 1.00 | infobox |
| Neuromyelitis optica spectrum disorder | Types | AQP4-IgG-positive, MOG-IgG-positive (recurrent, monophasic) | 1.00 | infobox |
| Neuromyelitis optica spectrum disorder | Usual onset | Median: age 40 for AQP4-IgG, age 31 for MOG-IgG | 1.00 | infobox |
| the area postrema | instance of | There is broad consensus that AQP4/NMO-IgG initially enters the brain via BBB-deficient sites | 0.80 | text |
| where there is access to cerebrospinal fluid | instance of | There is broad consensus that AQP4/NMO-IgG initially enters the brain via BBB-deficient sites | 0.80 | text |
